Chapter 6. Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Rajeev S. Bhide and
  2. Joseph Fargnoli

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch6

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Bhide, R. S. and Fargnoli, J. (2009) Discovery of Brivanib Alaninate: A Dual Vascular Endothelial Growth Factor and Fibroblast Growth Factor Receptor Inhibitor, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch6

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Keywords:

  • brivanib alaninate discovery;
  • VEGFR2 kinase domain;
  • dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)

Summary

This chapter contains sections titled:

  • Introduction

  • VEGFR and FGFR as Angiogenesis Targets

  • Discovery of Brivanib Alaninate: Preclinical Studies

  • Clinical Studies

  • Potential Liabilities of Antiangiogenic Therapy

  • Conclusions and Future Directions

  • Appendix: Formula for Calculation of Tumor Growth Inhibition

  • Acknowledgment

  • References